Rischin D - Search Results

1

Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.

Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G, Rischin D. Dawson SJ, et al. Among authors: rischin d. Anticancer Drugs. 2008 Jun;19(5):547-52. doi: 10.1097/CAD.0b013e3282fc6cf7. Anticancer Drugs. 2008. PMID: 18418222

2

Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer.

Millward MJ, Bishop JF, Friedlander M, Levi JA, Goldstein D, Olver IN, Smith JG, Toner GC, Rischin D, Bell DR. Millward MJ, et al. Among authors: rischin d. J Clin Oncol. 1996 Jan;14(1):142-8. doi: 10.1200/JCO.1996.14.1.142. J Clin Oncol. 1996. PMID: 8558189 Clinical Trial.

3

Association of acquired Pelger-Huet anomaly with taxoid therapy.

Juneja SK, Matthews JP, Luzinat R, Fan Y, Michael M, Rischin D, Millward MJ, Toner GC. Juneja SK, et al. Among authors: rischin d. Br J Haematol. 1996 Apr;93(1):139-41. doi: 10.1046/j.1365-2141.1996.4701020.x. Br J Haematol. 1996. PMID: 8611447

4

Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.

Rischin D, Webster LK, Millward MJ, Linahan BM, Toner GC, Woollett AM, Morton CG, Bishop JF. Rischin D, et al. J Natl Cancer Inst. 1996 Sep 18;88(18):1297-301. doi: 10.1093/jnci/88.18.1297. J Natl Cancer Inst. 1996. PMID: 8797769 Clinical Trial.

5

Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute.

Millward MJ, Webster LK, Toner GC, Bishop JF, Rischin D, Stokes KH, Johnston VK, Hicks R. Millward MJ, et al. Among authors: rischin d. Aust N Z J Med. 1996 Jun;26(3):372-9. doi: 10.1111/j.1445-5994.1996.tb01925.x. Aust N Z J Med. 1996. PMID: 8811211

6

Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.

Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC. Shapiro JD, et al. Among authors: rischin d. Gynecol Oncol. 1996 Oct;63(1):89-93. doi: 10.1006/gyno.1996.0284. Gynecol Oncol. 1996. PMID: 8898175 Clinical Trial.

7

Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.

Millward MJ, Zalcberg J, Bishop JF, Webster LK, Zimet A, Rischin D, Toner GC, Laird J, Cosolo W, Urch M, Bruno R, Loret C, James R, Blanc C. Millward MJ, et al. Among authors: rischin d. J Clin Oncol. 1997 Feb;15(2):750-8. doi: 10.1200/JCO.1997.15.2.750. J Clin Oncol. 1997. PMID: 9053501 Clinical Trial.

8

Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.

Shapiro JD, Millward MJ, Rischin D, Davison JD, Michael M, Francis PA, Ganju V, Toner GC. Shapiro JD, et al. Among authors: rischin d. Aust N Z J Med. 1997 Feb;27(1):40-4. doi: 10.1111/j.1445-5994.1997.tb00912.x. Aust N Z J Med. 1997. PMID: 9079252

9

A phase II trial of carboplatin and etoposide for relapsed or metastatic carcinoma of the cervix.

Tebbutt N, Rischin D, Quinn M, Rome R, Millward MJ, Toner GC, Bishop JF. Tebbutt N, et al. Among authors: rischin d. Aust N Z J Obstet Gynaecol. 1998 Feb;38(1):87-90. doi: 10.1111/j.1479-828x.1998.tb02967.x. Aust N Z J Obstet Gynaecol. 1998. PMID: 9521400 Clinical Trial.

10

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.

Zalcberg J, Millward M, Bishop J, McKeage M, Zimet A, Toner G, Friedlander M, Barter C, Rischin D, Loret C, James R, Bougan N, Berille J. Zalcberg J, et al. Among authors: rischin d. J Clin Oncol. 1998 May;16(5):1948-53. doi: 10.1200/JCO.1998.16.5.1948. J Clin Oncol. 1998. PMID: 9586914 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters